En undersøgelse til evaluering af effektiviteten af to doser AP-472 som supplement til levodopa hos deltagere med Parkinsons sygdom (PD) med motoriske udsving
Fase 2, dobbeltblind, placebo-kontrolleret undersøgelse for at evaluere effektiviteten af to doser AP-472 som adjuvans til levodopa hos deltagere med Parkinsons sygdom (PD) med motoriske fluktuationer
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.
The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.
The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Annie Blobaum, Ph.D.
- Telefonnummer: 615-427-1935
- E-mail: annie@appellopharma.com
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205-5551
- Rekruttering
- University of Arkansas for Medical Sciences (Site #208)
-
-
California
-
Carlsbad, California, Forenede Stater, 92011
- Rekruttering
- Profound Research LLC (Site #222)
-
Los Alamitos, California, Forenede Stater, 90720-3108
- Rekruttering
- Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217)
-
Los Angeles, California, Forenede Stater, 90033-5310
- Rekruttering
- Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
-
Palo Alto, California, Forenede Stater, 94301
- Rekruttering
- Parkinson's Research Centers of America (Site #218)
-
-
Colorado
-
Englewood, Colorado, Forenede Stater, 80113-2776
- Rekruttering
- Rocky Mountain Clinical Research - CenExel - PPDS (Site #215)
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33486
- Rekruttering
- Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227)
-
Boca Raton, Florida, Forenede Stater, 33486
- Rekruttering
- UM-UHealth at Boca Raton (Site #226)
-
Hallandale, Florida, Forenede Stater, 33009
- Rekruttering
- Velocity Clinical Research - Hallandale Beach (Site #228)
-
Miami, Florida, Forenede Stater, 33136-1051
- Rekruttering
- University of Miami (Site #220)
-
Orlando, Florida, Forenede Stater, 32825
- Rekruttering
- Neurology One (Site #205)
-
Tampa, Florida, Forenede Stater, 33613-4808
- Rekruttering
- USF Parkinson's Disease and Movement Disorders Center (Site #206)
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30912-0020
- Rekruttering
- Augusta University Medical Center (Site #212)
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46256
- Rekruttering
- Josephson Wallack Munshower Neurology PC (Site #231)
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- The University of Kansas (KU) (Site #216)
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536-0001
- Rekruttering
- Kentucky Neuroscience Institute (Site #213)
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215-5400
- Rekruttering
- Beth Israel Deaconess Medical Center (Site #211)
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan Health System (UMHS) (Site #202)
-
Farmington Hills, Michigan, Forenede Stater, 48334-2973
- Rekruttering
- Quest Research Institute - Alcanza - PPDS (Site #201)
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Rekruttering
- University of New Mexico Health Sciences Center (Site #225)
-
-
New York
-
New York, New York, Forenede Stater, 10029-6501
- Rekruttering
- Mount Sinai School of Medicine (Site #209)
-
New York, New York, Forenede Stater, 10021
- Rekruttering
- Joan and Sanford I. Weill Department of Medicine (Site #224)
-
-
North Carolina
-
Asheville, North Carolina, Forenede Stater, 28806
- Rekruttering
- Asheville Neurology Specialists, P.A. (Site #229)
-
Durham, North Carolina, Forenede Stater, 27705
- Rekruttering
- Duke Neurological Disorders Clinic (Site #210)
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195-0001
- Rekruttering
- Cleveland Clinic (Site #223)
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The Ohio State University Wexner Medical Center (site #207)
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Rekruttering
- Vanderbilt University Medical Center (Site #204)
-
-
Texas
-
Cypress, Texas, Forenede Stater, 77429
- Rekruttering
- Horizon Clinical Research: Gill Neuroscience - Houston (Site #232)
-
Round Rock, Texas, Forenede Stater, 78681-3578
- Rekruttering
- Central Texas Neurology Consultants (Site #203)
-
-
Washington
-
Kirkland, Washington, Forenede Stater, 98034-3013
- Rekruttering
- EvergreenHealth (Site #219)
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
Participants must meet all of the following criteria to take part in the study:
- Be a man or woman between 30 and 80 years of age at the time of screening.
- Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.
- Have mild to moderate Parkinson's disease, defined as stage 3 or lower on the Hoehn and Yahr scale when medications are working ("ON" state).
- Experience an average of at least 3 hours of OFF time per day, based on home symptom diaries, with at least 2.5 hours of OFF time each day during the baseline period.
- Have a Montreal Cognitive Assessment (MoCA) score of 24 or higher at screening.
- Be able to walk independently, with or without the use of a walking aid.
- Be able to swallow oral medication.
- Have been on a stable Parkinson's medication regimen for at least 4 weeks before screening. Medications known as MAO-B inhibitors must have been stable for at least 12 weeks.
- Be taking levodopa at least four times daily (immediate- or controlled-release formulations) or three times daily (extended-release formulations such as Rytary or Crexont).
Key Exclusion Criteria:
Participants cannot take part in the study if any of the following apply:
- Have a form of parkinsonism that is not typical Parkinson's disease, such as secondary or atypical parkinsonism.
- Have previously received, or plan to receive during the study, advanced Parkinson's therapies such as continuous levodopa or dopamine delivery systems, or Parkinson's disease-related brain surgery.
- Have dyskinesias (involuntary movements) that are severe enough, in the study doctor's opinion, to interfere with participation.
- Have a history of only certain types of dyskinesias (such as OFF-state, diphasic, myoclonic, or dystonic dyskinesias) without typical peak-dose dyskinesias.
- Are currently taking medications that block dopamine, except for low-dose quetiapine (up to 50 mg per day) used for insomnia.
- Routinely use on-demand "rescue" Parkinson's medications more than three times per week.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Oral tablet |
|
Eksperimentel: Low Dose
AP-472 100 mg per day |
Oral tablet Oral tablet |
|
Eksperimentel: High Dose
AP-472 300 mg per day |
Oral tablet |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring fra baseline i gennemsnitlig daglig OFF-tid på motordagbøger for AP-472 sammenlignet med placebo (normaliseret til 16 timers vågentid)
Tidsramme: Uge 12
|
Uge 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ændring fra baseline i ON-tid uden generende dyskinesi (normaliseret til 16 timer)
Tidsramme: Uge 12
|
Uge 12
|
|
|
Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 2 (Motor Experiences of Daily Living (M-EDL)) score
Tidsramme: Week 12
|
For MDS-UPDRS Part II (Motor Experiences of Daily Living, M-EDL) there are 13 items each scored from 0 to 4. The total score range is from 0-52. A higher score indicates worse motor impact on daily activities; lower scores are better. |
Week 12
|
|
Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index
Tidsramme: Week 12
|
For the Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index the score is calculated by averaging the 8 domain scores and converting them to a 0-100 scale. A higher score indicates worse health-related quality of life; lower scores are better. |
Week 12
|
|
Change from baseline in MDS-UPDRS Part III (Motor Examination) score in the best ON state
Tidsramme: Week 12
|
The MDS-UPDRS Part III includes 33 items, each scored from 0 to 4. The total score range is from 0-132. A higher score indicates worse motor impairment; lower scores are better. |
Week 12
|
|
Change from baseline in Epworth Sleepiness Scale (ESS) total score
Tidsramme: Week 12
|
The ESS consists of 8 items, each scored from 0 to 3. The total score range is from 0-24. Higher scores indicate greater daytime sleepiness; lower scores are better. |
Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- APLO-1201
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .